Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The pharmacy benefit manager Prime Therapeutics published an analysis last summer that highlights this ongoing challenge with respect to the real-world effectiveness over time of the GLP-1 drugs used to treat obesity: Most overweight or obese patients without diabetes stop treatment within the first few years
These include: Nausea (affecting 20-40% of patients initially) Vomiting Diarrhoea Constipation Abdominal discomfort These effects typically arise from delayed gastric emptying and direct effects on the gastrointestinal tract
Leave a review
June 16, 2023
Scand J Gastroenterol (2013) 48(10):11529.10.3109/00365521.2013.832366 172 LeeSJLeeJLiKKHollandDMaughanHGuttmanDSet alDisruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis
